Lynk Pharmaceuticals Co., Ltd., a China-based clinical stage pharmaceutical company, announced on Friday that it has collaborated with Simcere (2096.HK), a China-based manufacturer and supplier of branded generic pharmaceuticals in the Chinese market, for the development and commercialisation of a highly selective JAK1 inhibitor LNK01001 in China.
According to the terms of the contract, Lynk Pharmaceuticals will be responsible for the development of the product, while Simcere will receive the exclusive rights to market the product for the indications of rheumatoid arthritis and ankylosing spondylitis in China, after completing the payment of all commercialisation rights and interests.
Lynk says that LNK01001 is a highly selective JAK1 inhibitor with therapeutic potential for various autoimmune diseases. It is conducting clinical trials in Chinese and western patient groups, including phase II studies in China in three indications of rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis. The product has previously completed Phase one clinical studies in healthy subjects in China and Australia.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US